fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Enalapril maleate

All products: general benefit

Enalapril · DIN 02442957 · 2.5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Enalapril · DIN 02442957 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30 Daily cost (source): $0.1863 Health Canada: Marketed since 2018-10-04 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 2 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Enalapril: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1863). What the ministry pays, not the patient.

Ministry pays: $0.1863 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442957)

Source record
DIN 02442957: Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id SIV Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1863; ministry $0.1863 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442957 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92748
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863 Co Enalapril · DIN 02291878 · $0.1863 Enalapril · DIN 02400650 · $0.1863 Jamp-Enalapril · DIN 02474786 · $0.1863 Mar-Enalapril · DIN 02459450 · $0.1863 Mylan-Enalapril · DIN 02300036 · $0.1863 Novo-Enalapril · DIN 02300680 · $0.1863 Ran-Enalapril · DIN 02352230 · $0.1863 Ratio-Enalapril · DIN 02299984 · $0.1863 Sandoz Enalapril · DIN 02299933 · $0.1863 Taro-Enalapril · DIN 02300117 · $0.1863 Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended March 25, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442957
Shortage record checked October 6, 2026

Other products in the same Health Canada class (C09AA): coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, not a benefit
  • Captopril (Noyada): general benefit, limited Use 707, 723, not a benefit
  • Cilazapril (Inhibace): general benefit, not a benefit
  • Fosinopril (Monopril): general benefit, not a benefit
  • Lisinopril (Prinivil): general benefit, not a benefit
  • Perindopril erbumine (Coversyl): general benefit

3 more in the class list below

Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

LISINOPRIL

· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab

PERINDOPRIL ERBUMINE

· 48 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab

QUINAPRIL

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab

RAMIPRIL

· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (4), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (18), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: or renovascular hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CAPTOPRIL · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) INDICATIONS AND CLINICAL USE Hypertension APO-CAPTO (captopril) is indicated for the treatment of essential or renovascular hypertension. PM: https://pdf.hres.ca/dpd_pm/00022606.PDF; date November 1, 2013; DIN 00893595; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS VASOTEC® (enalapril) is indicated for:  essential or renovascular hypertension  treatment of symptomatic congestive heart failure Hypertension VASOTEC® is indicated in the treatment of essential or renovascular hypertension. It is usually administered in association with other drugs, particularly thiazide diuretics. In using VASOTEC® consideration should be given to the risk of angioedema (see 7 WARNINGS AND PRECAUTIONS). Congestive Heart Failure VASOTEC® is indicated in the treatment of symptomatic congestive heart failure usually in combination with diuretics and/or digitalis. In these patients, VASOTEC® improves symptoms, increases survival, and decreases the frequency of hospitali zation (see 14 CLINICAL TRIALS for details and limitations of survival trials). Treatment with VASOTEC® should be initiated under close medical supervision. In clinically stable asymptomatic patients with left ventricul ar dysfunction (ejection fraction ≤35%), VASOTEC® decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see 14 CLINICAL TRIALS for details and limitations of survival trials). 1.1 Pediatrics… https://pdf.hres.ca/dpd_pm/00061923.PDF PM date: not printed or not captured Source product: VASOTEC; DIN 00670901; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.